Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs - Wikidata - awgldk - TriplyDB

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs

http://www.wikidata.org/entity/Q35758996

about

Recent advances in the diagnosis and treatment of childhood tuberculosis Antituberculosis therapy for 2012 and beyond In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori Pipeline of drugs for related diseases: tuberculosis Recent advances in tuberculosis: New drugs and treatment regimens.Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.Discovery of dipiperidines as new antitubercular agents.Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.The chemical biology of new drugs in the development for tuberculosis.Design, synthesis, and biological evaluation of novel fluorinated ethanolamines.New approaches in the diagnosis and treatment of latent tuberculosis infection An update on the use of rifapentine for tuberculosis therapy.Current development and future prospects in chemotherapy of tuberculosis SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.New drugs to treat tuberculosis.New drugs and regimens for treatment of TB.Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Terpenyl-purines from the sea.Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro.Recent advances in antituberculous drug development and novel drug targets.Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.Tuberculosis drugs: new candidates and how to find more.Challenges and opportunities in developing novel drugs for TB.Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets.New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.Antituberculosis drug research: a critical overview.New treatment options for multidrug-resistant tuberculosis.Targeting the mycobacterial envelope for tuberculosis drug development.Novel diagnostics and therapeutics for drug-resistant tuberculosis.The anti-tuberculosis agents under development and the challenges ahead.Development of new antituberculosis drugs from natural products.Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.News on therapeutic management of MDR-tuberculosis: a literature review.Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects.Development of new antituberculous agents based on new drug targets and structure-activity relationship.Synthesis and 3D-QSAR analysis of 2-chloroquinoline derivatives as H37 RV MTB inhibitors.A comparative study on the activities of six combination regimens against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.Targeting protein biotinylation enhances tuberculosis chemotherapy.

P2860

Q26797426-6C8C0CFD-A8F2-43E6-A3EE-33DFAD11325B Q26829101-411B10F6-7A15-4C6B-A835-B04B97EA2E9F Q28534899-5E0B4EEE-838D-4AA2-9011-8BA7B3461DC3 Q28818217-77FC05BB-B85F-4574-9948-EE7398E7F093 Q30360811-8D6095BB-DCF6-46D9-AF20-A37EE294D435 Q30419537-A5EA4849-50CE-41E8-9556-42FABF6D7581 Q30886962-3E16D597-7096-49C3-8F83-3C370699D935 Q33361748-12139A24-0015-4193-876B-66DA541192A7 Q33962793-F7DE08DB-4EB1-4AC5-BB0A-D339877F7739 Q34054325-CA22374C-CEF8-41C0-9B14-E00AD01F1DD3 Q34082529-942C4609-5A92-4577-93C5-C8B2F94F0FC9 Q34419185-145D6D73-A8B7-4AE4-8559-9231675FFBC4 Q35084363-8CC90194-506E-4F6D-B881-534DBD5546EE Q35705874-5FE1806C-2F29-4E41-A18B-9AC8EB7C5056 Q35867500-8BFE6D19-3267-4749-ABDC-6162DECEA740 Q36018409-4A701DE4-987D-4416-AD2D-1C740AF2F1A1 Q36825354-1957C50E-65C2-4F67-B9D9-D9AC7C242FC2 Q37247725-630F31BC-B4C5-4E19-8A13-D60F94EBC73A Q37346929-A89BD99E-E941-4ABC-8E81-772CA2087516 Q37680690-8EE7B77A-FD42-4F50-87D8-99C2278878C4 Q37720810-A33DE35E-93AE-45A4-85A4-2C474135C796 Q37754884-9E1439EE-234E-4E0A-AC50-1469DBEBBA7C Q37845798-A5EC8A86-F1A3-40D5-A296-5244AF8AF5EF Q37894691-A4C50F2A-A9A1-4E23-9E40-E45043DEE389 Q37924294-D2C7B24F-9949-4C47-8E89-1C9F44CDDE97 Q37970706-159F679E-887D-4605-94AA-58A820F0FB5B Q37996998-D06BF49B-D9EE-4C9C-B042-7962C0638638 Q38012651-4C057132-97EB-409E-9A16-8A705E69CA5C Q38024041-DED06AE4-2BE0-4007-B84A-9D58646D74A3 Q38056149-28493EAB-56EB-4203-AB1E-C3A3C54C7CC2 Q38210363-8AC481CC-D2FE-4E8F-9F7C-0D5632268A0F Q38617197-AB8E40B6-79EE-4CB5-A87C-2FE3FCDD81B1 Q39019430-1AC8553F-823B-4499-A928-DBCE0B1E7D38 Q39062681-6FCC80DF-9C1E-44A1-BD2F-22D064AAAFF7 Q39398924-32610278-7E6D-435F-96E5-86A8C08284BA Q39967041-C92059B8-DAB7-43A2-AC66-E76C0E647968 Q40138610-85855055-038B-467B-9BB6-9F7FCF2A56F4 Q42710585-E0E6E3E0-3BC4-4611-BE30-B63F6FC6692E Q44002084-9A50A2B2-CD0E-46E6-AFBD-E87FB86F779E Q52562988-4B56313D-EBFF-4EC0-9C70-BE0D9C26C00F

P2860

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs

http://www.wikidata.org/entity/Q35758996

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Drug therapy of experimental t ...... biotic, with existing TB drugs

@ast

Drug therapy of experimental t ...... biotic, with existing TB drugs

@en

type

label

Drug therapy of experimental t ...... biotic, with existing TB drugs

@ast

Drug therapy of experimental t ...... biotic, with existing TB drugs

@en

prefLabel

Drug therapy of experimental t ...... biotic, with existing TB drugs

@ast

Drug therapy of experimental t ...... biotic, with existing TB drugs

@en

P1433

Q35758996-CE890376-0DB7-4409-99EF-41607413A96F

P1476

Q35758996-8F28E3F1-1BF3-4510-869B-37941B2D9FAE

P2093

Q35758996-55022B6A-DFF5-4AE7-8A10-E1181DE47B5A

Q35758996-6DDD0118-2AB4-44F9-B855-1A80F50F62A3

Q35758996-C50336E4-1CE8-4F84-8DF5-10D13766A83F

Q35758996-D20444CD-22DC-4540-A3E8-9A8BB486521D

Q35758996-EEEE75C1-E1A3-4ADE-8C50-1D70330749BD

P2860

Q35758996-0D4D052A-0F0D-4390-B2A8-ADEA39A8BA31

Q35758996-32C9668C-2BDC-45F1-808C-1B4A8F3F0E39

Q35758996-43B43F5C-7C8B-421F-957E-09CD49F94C12

Q35758996-4A017C8E-13ED-4118-9F43-85C153B159A6

Q35758996-6450E47C-849C-4B93-969D-DAB6B249B84C

Q35758996-87586D11-D0C6-4FDB-9573-813A4D3D1A03

Q35758996-8790CF46-2B88-4107-A24D-8F5040D8BC8E

Q35758996-A3731724-A66D-42C1-960E-35E776BA08D1

Q35758996-A5E26F11-4054-4A29-A850-9361F2BB957F

Q35758996-B4DF9EEF-DA61-42B5-925C-A73DA2FB5E62

P304

Q35758996-2CE200C4-C0F9-4256-840C-B00388B07F6D

P31

Q35758996-99D828BB-1F2B-4BF9-9DAC-34E619929827

P356

Q35758996-C9C1B5E7-49E0-409B-B8E5-69DE7FCD93E7

P407

Q35758996-451CB899-13F3-4E21-9452-0DB530F56A36

P433

Q35758996-49565E7A-942E-42B6-8610-FCCBBCB3F60E

P478

Q35758996-01D5D555-BE71-43D8-A728-B940FD0E1E8B

P577

Q35758996-A0008DE9-1CA5-4D4E-B1C3-D06AC17DDF36

P5875

Q35758996-0F67BD35-EBE7-4A88-95DF-F1DD7E0C3F7C

P698

Q35758996-17450A75-4A3F-42E5-9119-8060E509C303

P921

Q35758996-A404BB21-4862-41A5-A92C-AAD915578FB8

P932

Q35758996-9721D9BF-8650-4253-BD6D-3680D21DE081

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Drug therapy of experimental t ...... biotic, with existing TB drugs

@en

P2093

Boris V Nikonenko

http://www.w3.org/2001/XMLSchema#string

Carol A Nacy

http://www.w3.org/2001/XMLSchema#string

Leo Einck

http://www.w3.org/2001/XMLSchema#string

Marina Protopopova

http://www.w3.org/2001/XMLSchema#string

Rowena Samala

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.

Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.

Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis

P304

1563-1565

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01326-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6561225

http://www.w3.org/2001/XMLSchema#string

P698

17242141

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

1855523

http://www.w3.org/2001/XMLSchema#string